Wuxi Apptec Stock Price, News & Analysis

WuXi AppTec (OTC:WUXAY), a global pharmaceutical and life sciences R&D and manufacturing services provider, has earned the EcoVadis Gold Medal for sustainability for the second consecutive year. The rating evaluates companies across environment, labor & human rights, ethics, and sustainable procurement criteria.

The company has received multiple sustainability recognitions, including five consecutive years of MSCI ESG Leadership Rating, four consecutive years in the Dow Jones Sustainability Index, and its first MSCI ESG AAA rating. WuXi AppTec has also obtained validation from the Science Based Targets initiative (SBTi) for its emissions reduction targets and participates in the UN Global Compact.

WuXi AppTec (WUXAY) has completed its second RMB1.0 billion A-share repurchase program in 2025, with all repurchased shares scheduled for cancellation on August 28, 2025. The company repurchased 11,860,809 A-shares, representing 0.40% of total share capital, between June 26 and August 26, 2025.

This year, WuXi AppTec has executed RMB2.0 billion in total A-share repurchases. Combined with cash dividends, the company's shareholder returns in 2025 amount to RMB5.84 billion, exceeding 60% of the company's 2024 net profit attributable to owners.

WuXi AppTec (NASDAQ:WUXAY), a global pharmaceutical R&D and manufacturing services provider, has been included in the FTSE4Good Index Series for the third consecutive year. The company achieved the highest score of 5 points in Corporate Governance, Anti-Corruption, and Labor Standards in FTSE Russell's ESG assessment.

The company has received multiple ESG recognitions, including MSCI ESG Leadership Rating for five consecutive years, inclusion in the Dow Jones Sustainability Index for four consecutive years, and an A- Leadership rating in CDP Climate Change assessment. WuXi AppTec has also obtained SBTi validation for emissions reduction targets and participates in the UN Global Compact.

WuXi AppTec (WUXAY) reported strong financial results for Q2 and H1 2025, with significant growth across key metrics. Total revenue reached RMB20.80 billion in H1 2025, up 20.6% YoY, while revenue from continuing operations grew 24.2% YoY to RMB20.41 billion.

Key highlights include adjusted non-IFRS net profit of RMB6.31 billion (up 44.4% YoY), backlog growth of 37.2% YoY to RMB56.69 billion, and operating cash flow increase of 49.1% to RMB7.07 billion. The company's small molecule D&M pipeline expanded to 3,409 molecules, with 412 new molecules added in H1 2025.

Based on strong performance, WuXi AppTec raised its 2025 guidance, now expecting continuing operations revenue growth of 13-17% and total revenue of RMB42.5-43.5 billion. The company also announced its first interim dividend of RMB3.50 per 10 shares.

WuXi AppTec (WUXAY), a global pharmaceutical and life sciences technology platform company, has released a positive profit alert for H1 2025. The company expects total revenue of RMB20.80 billion, up 20.6% year-over-year, with revenue from Continuing Operations growing 24.2%.

Key financial highlights include an expected adjusted non-IFRS net profit of RMB6.31 billion (up 44.4% YoY), net profit after non-recurring items of RMB5.58 billion (up 26.5% YoY), and net profit attributable to owners of RMB8.56 billion (up 101.9% YoY). Basic earnings per share is projected at RMB3.01, representing a 106.2% increase.

WuXi AppTec (WUXAY) has completed significant share repurchase and acquisition activities in Q2 2025. The company executed an RMB1.0 billion A-share repurchase program, buying back 15,775,377 A-shares at RMB63.39 per share (0.55% of total shares) between April 18 and June 20, 2025, which were subsequently cancelled on June 24.

Additionally, the company acquired HKD2.5 billion worth of H-shares (34,092,975 shares, 1.19% of total shares) through its 2025 H Share Award and Trust Scheme. The H-share acquisition is tied to revenue targets, with HKD1.5 billion in shares to be granted if 2025 revenue reaches RMB42.0 billion, and an additional HKD1.0 billion if revenue hits RMB43.0 billion.

WuXi AppTec (WUXAY) has achieved the highest possible MSCI ESG rating of AAA, becoming the first A-share listed company in the life science industry to reach this milestone. The company earned this distinction for excellence in Product Safety and Quality, Human Capital Development, and Corporate Governance, upgrading from its previous AA rating maintained for four consecutive years.

The achievement is complemented by WuXi AppTec's other sustainability recognitions, including four consecutive years in the Dow Jones Sustainability Index, A- Leadership rating in CDP Climate Change assessment, and Gold Medal in EcoVadis sustainability rating. The company has also received validation from the Science Based Targets initiative (SBTi) for its emissions reduction targets and participates in the UN Global Compact.

WuXi AppTec (OTC:WUXAY), a global provider of R&D and manufacturing services for the pharmaceutical industry, announced that its Nantong site (Phase I) has won the Popular Choice Winner award in the "Factory & Warehouse" category at the 2025 Architizer A+Awards.

The Nantong site, located in Jiangsu province, China, features eight main buildings arranged in two clusters and serves as a key component of WuXi AppTec's CRDMO platform. The facility's design emphasizes 'technological-humanistic symbiosis', incorporating operational efficiency with human-centered design elements. The site provides comprehensive chemistry, biology, and testing solutions to global customers.

WuXi AppTec (WUXAY) has received validation from the Science Based Targets initiative (SBTi) for its near-term emissions reduction targets, demonstrating alignment with global efforts to limit temperature rise to 1.5°C. The company commits to reducing absolute Scope 1 and 2 GHG emissions by 42% by 2030 from 2024 levels, and Scope 3 emissions from purchased goods and services by 25%. To achieve these targets, WuXi AppTec is implementing various measures including process optimization, equipment upgrades, infrastructure renovation, and increasing renewable energy usage. The company has garnered multiple sustainability recognitions, including an AA rating in MSCI ESG ratings, inclusion in the Dow Jones Sustainability Index, and an A- Leadership rating in CDP Climate Change rating. As a global provider of R&D and manufacturing services for pharmaceutical and life science industries, WuXi AppTec has also joined the UN Global Compact and Pharmaceutical Supply Chain Initiative.